This kit can be used in quantitative and qualitative analysis of vancomycin residue in biological samples.
Contents of Kit
No.
Components
Size
Storage Conditions
1
Microtiter plate
96 wells
2-8°C
2
Vancomycin standard 1ppm
1 ml
2-8°C
3
Vancomycin standard 0ppb
1 ml
2-8°C
4
Vancomycin standard 0.5ppb
1 ml
2-8°C
5
Vancomycin standard 1.5ppb
1 ml
2-8°C
6
Vancomycin standard 4.5ppb
1 ml
2-8°C
7
Vancomycin standard 13.5ppb
1 ml
2-8°C
8
Vancomycin standard 40.5ppb
1 ml
2-8°C
9
Sample dilution
50 ml
2-8°C
10
Antibody solution
7 ml
2-8°C
11
Enzyme conjugate
12 ml
2-8°C
12
Substrate
2×6 ml
2-8°C
13
Stop Solution
7 ml
2-8°C
14
20×Wash buffer
50 ml
2-8°C
Storage
Store the kit at 2 - 8°C until expiration date.
General Description
Vancomycin is an antibiotic used to treat a number of bacterial infections. It is recommended intravenously as a first-line treatment for complicated skin infections, bloodstream infections, endocarditis, bone and joint infections, and meningitis caused by methicillin-resistant S.aureus. Blood levels may be measured to determine the correct dose.
Citations
Publication ()
Have you cited DEIANJ11 in a publication? Let us know and earn a reward for your research.
One-Step Detection of Vancomycin in Whole Blood Using the Lateral Flow Immunoassay
Applications: ELISA Reactive species: Human
"Abstract: Vancomycin (VAN) is an effective antibiotic against Gram-positive bacteria and the first-line therapy to prevent and treat methicillin-resistant Staphylococcus aureus (MRSA) and severe infections. However, low concentrations of VAN can result in resistant strains. High doses of VAN can cause nephrotoxicity and ototoxicity; thus, VAN is a representative drug for which drug monitoring is recommended. Several methods have been proposed to detect VAN. Among them, lateral flow immunoassays (LFIAs) have advantages, such as simple and user-friendly operation, low sample volume requirement, and cost effectiveness. In this study, we developed an LFIA capable of rapid on-site detection such that the VAN concentration in plasma could be monitored within 20 min by a one-step detection process using whole blood without plasma separation. VAN can be detected in whole blood over a wide range of concentrations (20-10,000 ng/mL), and the LFIA reported here has a detection limit of 18 ng/mL. The applicability of the developed LFIA compared to the results of measuring VAN with a commercial enzyme-linked immunosorbent assay kit showed a satisfactory correlation (Spearman's rho, ρ = 0.891). Therefore, the developed LFIA enables rapid and wide-range VAN detection in whole blood and can aid in drug monitoring to evaluate patients' responses to treatment." Article snippet: The mouse anti-vancomycin antibody (clone 30, CABT-LH054, 1 mg), a purified IgG type, along with the human vancomycin ELISA kit (DEIANJ11) that operates based on the indirect competitive assay principle for human serum and plasma samples, were acquired from Creative Diagnostics (Shirley, NY, USA).
Figure 1. Analytical sensitivity of the developed LFIA for VAN detection in whole blood.
Therapeutic Drug Distribution across the Mouse Brain Is Heterogeneous as Revealed by In Vivo, Spatially Resolved Aptamer-Based Sensing
Karen Scida, Elysse Ornelas-Gatdula, Michael DePasquale, Gregory V Carr, Netzahualcóyotl Arroyo-Currás
ACS Pharmacol Transl Sci2025 Jan 10PubMed ID: 39990862Read Article
Applications: ELISA Reactive species: Unspecified reactive species
"Abstract: Drug discovery for central nervous system (CNS) targets is a high stakes process with estimated success rates below ten percent. Dose scaling, penetration through the blood-brain-barrier (BBB), and potency are among the various challenges involved in developing drugs for CNS targets. The standard approach to evaluate some of these parameters is dosing lead therapeutic compounds via intravenous delivery and assessing their brain levels via tissue homogenization and ex vivo quantification. Although a cost and time effective approach, brain homogenization lacks pharmacokinetic spatial resolution and normalizes drug levels to the entire brain volume. The brain, however, is known to have regional differences in cellular composition, transporters, BBB permeability, and drug-metabolizing enzymes, factors that could significantly affect pharmacological assessments during drug discovery. In this study we employ electrochemical aptamer-based sensors, a technology that allows in situ, real-time molecular monitoring in live animals, to reveal significant differences in the pharmacokinetics of drug uptake and accumulation in the brain of mice. Using vancomycin in the context of penetrating brain injury (PBI), our results highlight that potency may be significantly affected by PBI location. Additionally, more accurate dose scaling and delivery for deep brain wounds could be achieved by adjusting route of administration based on real-time-measured pharmacokinetic profiles, for example by changing delivery from intravenous to intracerebroventricular dosing. We emphasize the issue of establishing accurate pharmacological parameters during preclinical drug discovery efforts and underline the value of aptamer-based sensors for precise estimations of drug pharmacokinetics, transport across the BBB, and effective dose delivery during preclinical trials." Article snippet: A Human Vancomycin ELISA Kit (Creative Diagnostics, Cat. #DEIANJ11) was utilized to determine the vancomycin concentration in mouse brain tissue specimens and all reagents provided were brought to room temperature prior to use.
Figure 1. Vancomycin pharmacokinetics and distribution are heterogeneous across brain regions.
Background
Vancomycin is a glycopeptide antibiotic that is derived from the fermentation of certain microorganisms, such as Amycolatopsis orientalis. It is primarily used to treat infections caused by gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and other resistant strains. Vancomycin exhibits potent bactericidal activity by interfering with various bacterial processes. Vancomycin works by inhibiting the synthesis of the bacterial cell wall, a crucial protective layer in Gram-positive bacteria. It specifically targets the D-alanyl-D-alanine precursor required for cell wall synthesis. By binding to these precursors, vancomycin prevents the cross-linking of peptidoglycan strands, leading to the weakening and eventual lysis of the bacterial cell wall. In addition, vancomycin also interferes with RNA synthesis in bacteria by binding to bacterial ribosomes. This inhibits protein synthesis, further compromising bacterial viability. Furthermore, vancomycin has been shown to affect bacterial cell membrane permeability. It disrupts the integrity of the bacterial cell membrane, leading to leakage of intracellular substances and ultimately cell death.
Figure 1. The mode of action of vancomycin in S. aureus. (Source: Hu, Q. et al., 2016)
Despite its efficacy, the clinical use of vancomycin is associated with certain risks. Nephrotoxicity, which refers to kidney damage, and hypersensitivity reactions are well-known adverse effects of intravenous vancomycin administration. To ensure optimal use and minimize the risk of toxicity, measurement of vancomycin plasma levels is crucial in clinical practice. Therapeutic drug monitoring (TDM) involves regularly monitoring the concentration of vancomycin in the bloodstream. This allows healthcare professionals to adjust the dosage to maintain therapeutic levels within a safe and effective range. Creative Diagnostics offers the Human Vancomycin ELISA Kit for the detection and quantification of vancomycin residues in biological samples. This kit provides a sensitive and accurate tool for determining vancomycin levels, facilitating therapeutic drug monitoring, and ensuring appropriate dosage adjustments for optimal care.
Alternative Names
Human Vancocin ELISA Human Vancomycin(VM) ELISA Human Vancocin ELISA Kit Human Vancomycin(VM) ELISA Kit
References
1. Hu Q, et al. Molecular events for promotion of vancomycin resistance in vancomycin intermediate Staphylococcus aureus. Frontiers in Microbiology. 2016, 7: 1601.
Q: Does this item contain H2O2 (Hydrogen peroxide)? If yes, please let us know the concentration in liquid/lyophilized.
A: NONE
Q: The expression host of the standard
A: None,it's synthetic
Q: What is the limit of quantification of this assay?
A: 0.34 nM
Customer Reviews
My Review for Human Vancomycin ELISA Kit
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.
References
Bactericidal coating to prevent early and delayed implant-related infections
JOURNAL OF CONTROLLED RELEASE
Authors: Jahanmard, F.; Croes, M.; Castilho, M.; Majed, A.; Steenbergen, M. J.; Lietaert, K.; Vogely, H. C.; van der Wal, B. C. H.; Stapels, D. A. C.; Malda, J.; Vermonden, T.; Yavari, S. Amin
The occurrence of an implant-associated infection (IAI) with the formation of a persisting bacterial biofilm remains a major risk following orthopedic biomaterial implantation. Yet, progress in the fabrication of tunable and durable implant coatings with sufficient bactericidal activity to prevent IAI has been limited. Here, an electrospun composite coating was optimized for the combinatorial and sustained delivery of antibiotics. Antibiotics-laden poly(e-caprolactone) (PCL) and poly'1q' (lactic-co glycolic acid) (PLGA) nanofibers were electrospun onto lattice structured titanium (Ti) implants. In order to achieve tunable and independent delivery of vancomycin (Van) and rifampicin (Rif), we investigated the influence of the specific drug-polymer interaction and the nanofiber coating composition on the drug release profile and durability of the polymer-Ti interface. We found that a bi-layered nanofiber structure, produced by electrospinning of an inner layer of [PCL/Van] and an outer layer of [PLGA/Rif], yielded the optimal combinatorial drug release profile. This resulted in markedly enhanced bactericidal activity against planktonic and adherent Staphylococcus aureus for 6 weeks as compared to single drug delivery. Moreover, after 6 weeks, synergistic bacterial killing was observed as a result of sustained Van and Rif release. The application of a nanofiber-filled lattice structure successfully prevented the delamination of the multi-layer coating after press-fit cadaveric bone implantation. This new lattice design, in conjunction with the multi-layer nanofiber structure, can be applied to develop tunable and durable coatings for various metallic implantable devices. This is particularly appealing to tune the release of multiple antimicrobial agents over a period of weeks to prevent early and delayed onset JAI.
Can Population Pharmacokinetics of Antibiotics be Extrapolated? Implications of External Evaluations
Background and objective External evaluation is an important issue in the population pharmacokinetic analysis of antibiotics. The purpose of this review was to summarize the current approaches and status of external evaluations and discuss the implications of external evaluation results for the future individualization of dosing regimens. Methods We systematically searched the PubMed and EMBASE databases for external evaluation studies of population analysis and extracted the relevant information from these articles. A total of 32 studies were included in this review. Results Vancomycin was investigated in 17 (53.1%) articles and was the most studied drug. Other studied drugs included gentamicin, tobramycin, amikacin, amoxicillin, ceftaroline, meropenem, fluconazole, voriconazole, and rifampicin. Nine (28.1%) studies were prospective, and the sample size varied widely between studies. Thirteen (40.6%) studies evaluated the population pharmacokinetic models by systematically searching for previous studies. Seven (21.9%) studies were multicenter studies, and 27 (84.4%) adopted the sparse sampling strategy. Almost all external evaluation studies of antibiotics (93.8%) used metrics for prediction-based diagnostics, while relatively fewer studies were based on simulations (46.9%) and Bayesian forecasting (25.0%). Conclusion The results of external evaluations in previous studies revealed the poor extrapolation performance of existing models of prediction- and simulation-based diagnostics, whereas the posterior Bayesian method could improve predictive performance. There is an urgent need for the development of standards and guidelines for external evaluation studies.
Optimizing the Clinical Use of Vancomycin
Antimicrobial Agents and Chemotherapy
Authors: Álvarez R, López Cortés L E, Molina J, et al.
The increasing number of infections produced by beta-lactam–resistant Gram-positive bacteria and the morbidity secondary to these infections make it necessary to optimize the use of vancomycin. In 2009, the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Disease Pharmacists published specific guidelines about vancomycin dosage and monitoring. However, these guidelines have not been updated in the past 6 years. This review analyzes the new available information about vancomycin published in recent years regarding pharmacokinetics and pharmacodynamics, serum concentration monitoring, and optimal vancomycin dosing in special situations (obese people, burn patients, renal replacement therapy, among others). Vancomycin efficacy is linked to a correct dosage which should aim to reach an area under the curve (AUC)/MIC ratio of ≥400; serum trough levels of 15 to 20 mg/liter are considered a surrogate marker of an AUC/MIC ratio of ≥400 for a MIC of ≤1 mg/liter. For Staphylococcus aureus strains presenting with a MIC >1 mg/liter, an alternative agent should be considered. Vancomycin doses must be adjusted according to body weight and the plasma trough levels of the drug. Nephrotoxicity has been associated with target vancomycin trough levels above 15 mg/liter. Continuous infusion is an option, especially for patients at high risk of renal impairment or unstable vancomycin clearance. In such cases, vancomycin plasma steady-state level and creatinine monitoring are strongly indicated.
ELISA-based detection of gentamicin and vancomycin in protein-containing samples
SpringerPlus
Authors: Odekerken J C E, Logister D M W, Assabre L, et al.
Background Orthopaedic implant infections are treated by surgical debridement, systematic antibiotic treatment or local antibiotic treatment with antibiotic-loaded beads. Currently antibiotic concentrations in wound exudate, serum, urine or tissue samples are determined with HPLC or fluorescent spectrometric assays. Both methods are heavily influenced due to proteins in the samples. Questions/purposes Is ELISA capable to detect gentamicin and vancomycin in protein-containing samples like serum and wound exudate. Methods Two specific competitive ELISA-assays were set-up to detect either gentamicin or vancomycin in protein-rich samples. An antibiotic-BSA hapten was generated as a coatable antigen and commercially available antibodies were applied for downstream immunodetection. Results The developed ELISAs perform at a detection range of 2–500 ng/ml gentamycin and 20–5000 ng/ml vancomycin. Both ELISAs were capable of detecting these antibiotics in human serum and wound exudate without being compromised by the presence of proteins. We did not detect cross-reactivity for gentamicin in the vancomycin ELISA or vice versa. Conclusions The antibiotic ELISAs detect gentamicin and vancomycin at low concentrations in protein-rich samples and they can be used as a high throughput and cost-effective alternative for chromatographic or fluorescent methods. Clinical relevance These ELISAs can be used to detect very low gentamicin or vancomycin concentrations in clinical samples or assess novel orthopaedic antibiotic release systems in in vitro and in vivo studies.
COA
Loading ......
Publication ()
Figure 1. Analytical sensitivity of the developed LFIA for VAN detection in whole blood. 
Figure 1. Vancomycin pharmacokinetics and distribution are heterogeneous across brain regions. 
Figure 1. The mode of action of vancomycin in S. aureus.
